Why Antidepressants Can Initially Worsen Anxiety and How to Manage It

The episode addresses the paradoxical initial worsening of anxiety and depression when starting antidepressants, particularly SSRIs. Dr. Tracey Marks explains that while these medications are prescribed to alleviate these conditions, they can trigger an acute increase in symptoms, especially anxiety, which can be more severe than the initial state. This transient effect is a significant barrier to treatment adherence and understanding its mechanism is crucial for both patients and clinicians.

The core mechanism involves serotonin activating not only beneficial pathways but also a pathway that releases corticotrophin-releasing factor (CRF), a hormone that triggers the body's fight-or-flight response. This explains the initial anxiety spike. The podcast distinguishes between this anxiety-provoking effect and other common initial side effects like nausea or sleep disturbances. It also highlights that this problem is more common and pronounced in individuals prone to anxiety compared to those with depression without significant anxiety. Furthermore, it differentiates bupropion (Wellbutrin), which works via dopamine and avoids serotonin-related blunting but can still cause activation through its own stimulating effects.

To mitigate this initial worsening, Dr. Marks recommends a "start low, go slow" approach, known as titration, where the medication dose is gradually increased over time. Clinicians often co-prescribe short-term benzodiazepines (e.g., clonazepam, lorazepam) to manage acute anxiety during the initial titration phase, tapering them off once the antidepressant's therapeutic effects stabilize. Patients are advised to communicate with their doctor about a titration schedule and to monitor for persistent severe activation, which might necessitate discontinuing the medication and trying an alternative.

This discussion underscores the complexity of psychopharmacology and the individualized nature of treatment response. It highlights ongoing research into blocking the CRF pathway to improve initial antidepressant tolerability. The episode implicitly emphasizes the importance of patient education, managing expectations, and collaborative decision-making between patients and psychiatrists to navigate the challenging initial phase of antidepressant treatment, ultimately improving adherence and long-term outcomes for mental health conditions.

"If we use antidepressants to treat anxiety, why do they make you more anxious at first?"

"The problem is more pronounced though with anxiety. Taking it can make your anxiety spike and even make you feel worse than before you took the medication."

"Serotonin activates one pathway that helps mood and anxiety, but it also activates another pathway that increases the brain chemical corticotrophin releasing factor, also called corticotrophin releasing hormone."

"So what they found is that serotonin can trigger the stress response through the corticotrophin hormone release."

"The main thing in treating anxiety is to start low and increase slowly to reach the therapeutic dose or the dose as expected to work. And we call this titration."

"Keep in mind every time you increase the dose, it could aggravate your anxiety."

"So one way we deal with this is to prescribe a benzodiazepine or benzos, for short, like clonazepam or lorazepam to reduce your anxiety and make the titration period smoother."

"Buproprion has its own issues with increasing activation through the dopamine system."

"Buproprion avoids this, but it also has a stimulating effect that can increase anxiety and make you feel agitated, irritable, or interfere with your sleep."